What is the recommended treatment for Strep gallolyticus (Streptococcus gallolyticus) bacteremia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The recommended treatment for Streptococcus gallolyticus bacteremia is intravenous penicillin G (12-18 million U/24 h) or ceftriaxone (2 g/24 h) for 4 weeks, as outlined in the American Heart Association guidelines 1.

Key Considerations

  • For penicillin-allergic patients, vancomycin (30 mg/kg per 24 h) is an appropriate alternative, but its use should be guided by susceptibility testing and consultation with an infectious diseases specialist 1.
  • Combination therapy with gentamicin (3 mg/kg per 24 h) may be considered for the first 2 weeks in cases of endocarditis, but its use should be carefully weighed against the risk of nephrotoxicity and ototoxicity 1.
  • It's crucial to search for an underlying source, particularly colorectal cancer, as S. gallolyticus bacteremia is strongly associated with gastrointestinal malignancies, and a colonoscopy should be performed even in asymptomatic patients 1.
  • Endocarditis is another common complication, occurring in a significant proportion of cases, so echocardiography is essential to guide treatment duration and intensity 1.
  • Treatment duration should be extended to 4-6 weeks if endocarditis is confirmed, and the choice of antibiotic regimen should be guided by susceptibility testing and clinical response 1.

Antibiotic Regimens

  • Penicillin G: 12-18 million U/24 h IV, either continuously or in 4-6 equally divided doses, for 4 weeks 1.
  • Ceftriaxone: 2 g/24 h IV or IM, in 1 dose, for 4 weeks 1.
  • Vancomycin: 30 mg/kg per 24 h IV, in 2 equally divided doses, for 4 weeks, with trough levels monitored to ensure efficacy and minimize toxicity 1.
  • Gentamicin: 3 mg/kg per 24 h IV or IM, in 1 dose, for the first 2 weeks, with careful monitoring of renal function and auditory function 1.

From the FDA Drug Label

The FDA drug label does not answer the question.

From the Research

Treatment of Strep gallolyticus Bacteremia

The treatment of Strep gallolyticus bacteremia typically involves the use of antibiotics. According to the study 2, Streptococcus gallolyticus was 100% sensitive to cefotaxime and vancomycin.

Antibiotic Sensitivities

  • Cefotaxime: 100% sensitive 2
  • Vancomycin: 100% sensitive 2
  • Penicillin: 81.2% sensitive 3
  • Ceftriaxone: all isolates were susceptible 3
  • Ampicillin: resistance was seen in only one of the isolates 3
  • Clindamycin, erythromycin, and tetracycline: highly resistant 2

Clinical Considerations

In addition to antibiotic treatment, it is essential to investigate for underlying conditions such as colon cancer, as there is a strong association between Strep gallolyticus bacteremia and colonic neoplasia 4, 5, 6. However, the study 3 found that colonic neoplasia and infective endocarditis were rare in their patients.

Patient Management

  • Colonoscopy is recommended in patients with Strep gallolyticus endocarditis or bacteremia to evaluate the possibility of high-grade adenoma or colon cancer 4
  • Preendoscopic antibiotics use can be considered in high-risk individuals 4
  • Patients with Strep gallolyticus bacteremia should be thoroughly evaluated for underlying co-morbidities, such as diabetes mellitus and chronic liver disease 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Streptococcus gallolyticus bacteraemia in hepatobiliary-pancreatic and colonic pathologies.

QJM : monthly journal of the Association of Physicians, 2014

Research

Streptococcus gallolyticus Bacteremia: An Experience from a Tertiary Center in South India.

Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.